Probity Advisors Inc. Decreases Stock Holdings in Gilead Sciences, Inc. $GILD

Probity Advisors Inc. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.8% in the second quarter, HoldingsChannel reports. The firm owned 13,516 shares of the biopharmaceutical company’s stock after selling 390 shares during the period. Probity Advisors Inc.’s holdings in Gilead Sciences were worth $1,499,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Phoenix Financial Ltd. lifted its stake in shares of Gilead Sciences by 5.9% during the 2nd quarter. Phoenix Financial Ltd. now owns 10,094 shares of the biopharmaceutical company’s stock worth $1,119,000 after purchasing an additional 564 shares during the last quarter. Avidian Wealth Enterprises LLC increased its holdings in shares of Gilead Sciences by 3.8% during the second quarter. Avidian Wealth Enterprises LLC now owns 10,044 shares of the biopharmaceutical company’s stock valued at $1,114,000 after acquiring an additional 367 shares in the last quarter. Bogart Wealth LLC raised its position in shares of Gilead Sciences by 2.7% in the 2nd quarter. Bogart Wealth LLC now owns 69,250 shares of the biopharmaceutical company’s stock valued at $7,678,000 after purchasing an additional 1,815 shares during the last quarter. Drive Wealth Management LLC raised its position in shares of Gilead Sciences by 28.9% in the 2nd quarter. Drive Wealth Management LLC now owns 4,672 shares of the biopharmaceutical company’s stock valued at $518,000 after purchasing an additional 1,048 shares during the last quarter. Finally, Princeton Global Asset Management LLC raised its position in shares of Gilead Sciences by 58.2% in the 2nd quarter. Princeton Global Asset Management LLC now owns 791 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 291 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Trading Up 0.2%

Shares of NASDAQ:GILD opened at $123.11 on Tuesday. Gilead Sciences, Inc. has a 52-week low of $85.60 and a 52-week high of $124.11. The stock has a market cap of $152.76 billion, a price-to-earnings ratio of 24.52, a PEG ratio of 0.84 and a beta of 0.34. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The business has a 50-day moving average price of $115.27 and a 200-day moving average price of $110.62.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period last year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the sale, the chief executive officer directly owned 591,203 shares of the company’s stock, valued at $66,013,726.98. This trade represents a 1.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the sale, the chief financial officer directly owned 157,055 shares in the company, valued at approximately $18,545,054.40. This trade represents a 1.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,500 shares of company stock valued at $8,281,540 over the last ninety days. Company insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on GILD. The Goldman Sachs Group increased their price objective on shares of Gilead Sciences from $105.00 to $108.00 and gave the company a “neutral” rating in a research report on Friday. Royal Bank Of Canada increased their price objective on shares of Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 8th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Finally, JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $121.14.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.